Louis Matis

Louis A. Matis, M.D. is the senior vice president and chief scientific officer at Evolveimmune. He has more than 30 years of broad-based experience and expertise encompassing clinical medicine, drug development, regulatory affairs, basic and clinical biomedical research, and executive leadership in biotechnology. Prior to EvolveImmune, Dr. Matis was the senior vice president and chief development officer at Pieris Pharmaceuticals from 2015-2020. He has also served as an executive director at Alexion Pharmaceuticals (2011-2015), as president and CEO of the Immune Tolerance Institute (2006-2011) and as president and CEO of CGI Pharmaceuticals (2000-2006). Dr. Matis began his career in biotechnology at Alexion Pharmaceuticals in 1993, where he was the company’s first chief scientific officer. Dr. Matis has held senior research and clinical positions at the National Cancer Institute, National Institutes of Health, and the FDA Center for Biologics Evaluation and Research.

Dr. Matis completed his clinical training in internal medicine at the University of Chicago and in medical oncology at the National Cancer Institute. He received his M.D. degree from the University of Pennsylvania, where he currently serves on the Board of Trustees, and his BA degree, summa cum laude, from Amherst College. Dr. Matis has received the NIH Award of Merit, FDA’s Commendable Service Award, and was elected to membership in the American Society for Clinical Investigation. Dr. Matis is the author of over 120 publications in the fields of immunology, cell and molecular biology, and clinical medicine, published in journals including Nature, Science, Cell, and the Proceedings of the National Academy of Sciences.